You are viewing the site in preview mode
Skip to main content
| |
APOE PRS
|
Non-APOE PRS
|
|---|
| |
Total sample (n = 818)
|
|
PRS version
|
β
|
SE
|
95% CI
|
p
|
β
|
SE
|
95% CI
|
p
|
|
34-SNP PRS
|
0.19
|
0.02
|
0.14–0.23
|
2e−17
|
0.06
|
0.02
|
0.02–0.10
|
2e−3
|
|
5e−8 PRS
|
0.19
|
0.02
|
0.15–0.23
|
3e−18
|
0.08
|
0.02
|
0.03–0.12
|
3e−4
|
|
1e−5 PRS
|
0.18
|
0.02
|
0.13–0.22
|
8e−16
|
0.05
|
0.02
|
0.004–0.09
|
0.03
|
|
PHS*
|
0.18
|
0.02
|
0.13–0.22
|
7e−15
|
0.11
|
0.04
|
0.03–0.18
|
8e−3
|
| |
Cogn unimpaired (n = 236)
|
|
β
|
SE
|
95% CI
|
p
|
β
|
SE
|
95% CI
|
p
|
|
34-SNP PRS
|
0.16
|
0.05
|
0.05–0.27
|
3e−3
|
0.02
|
0.04
|
− 0.07 to 0.10
|
0.7
|
|
5e−8 PRS
|
0.20
|
0.05
|
0.09–0.31
|
3e−4
|
0.08
|
0.04
|
− 0.003 to 0.17
|
0.06
|
|
1e−5 PRS
|
0.18
|
0.06
|
0.07–0.28
|
2e−3
|
0.04
|
0.05
|
− 0.05 to 0.13
|
0.4
|
|
PHS*
|
0.19
|
0.06
|
0.08–0.30
|
1e−3
|
0.13
|
0.10
|
− 0.08 to 0.33
|
0.2
|
| |
MCI (n = 434)
|
|
β
|
SE
|
95% CI
|
p
|
β
|
SE
|
95% CI
|
p
|
|
34-SNP PRS
|
0.21
|
0.03
|
0.15–0.27
|
8e−13
|
0.09
|
0.03
|
0.04–0.15
|
1e−3
|
|
5e−8 PRS
|
0.21
|
0.03
|
0.15–0.26
|
2e−12
|
0.08
|
0.03
|
0.03–0.14
|
1e−4
|
|
1e−5 PRS
|
0.19
|
0.03
|
0.14–0.25
|
4e−11
|
0.06
|
0.03
|
0.004–0.12
|
0.04
|
|
PHS*
|
0.18
|
0.03
|
0.13–0.24
|
2e−9
|
0.11
|
0.06
|
0.004–0.22
|
0.04
|
| |
AD (n = 148)
|
|
β
|
SE
|
95% CI
|
p
|
β
|
SE
|
95% CI
|
p
|
|
34-SNP PRS
|
0.13
|
0.03
|
0.07–0.19
|
6e−5
|
0.03
|
0.03
|
− 0.03 to 0.09
|
0.4
|
|
5e−8 PRS
|
0.12
|
0.03
|
0.06–0.18
|
7e−5
|
0.03
|
0.03
|
− 0.04 to 0.09
|
0.4
|
|
1e−5 PRS
|
0.13
|
0.03
|
0.07–0.19
|
7e−5
|
0.03
|
0.03
|
− 0.04 to 0.09
|
0.4
|
|
PHS*
|
0.12
|
0.03
|
0.06–0.18
|
1e−4
|
0.06
|
0.05
|
− 0.04 to 0.15
|
0.2
|
- Results within the total sample are adjusted for sex, age, principal components, and diagnostic status. Results within the diagnostic groups are adjusted for sex, age, and principal components. Significant p values are shown in bold
- *Values presented in the “non-APOE PRS column” are adjusted for ε4-carriership instead of excluding APOE
